Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib as Second-line Therapy in Malignant Melanoma
NCT03383237Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in Malignant Melanoma (MM), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT03383237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383237.